These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 9791040)

  • 21. Renal and hormonal effects of chronic inhibition of neutral endopeptidase (EC 3.4.24.11) in normal man.
    O'Connell JE; Jardine AG; Davies DL; McQueen J; Connell JM
    Clin Sci (Lond); 1993 Jul; 85(1):19-26. PubMed ID: 8149689
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dietary sodium and inhibition of neutral endopeptidase 24.11 in essential hypertension.
    Singer DR; Markandu ND; Buckley MG; Miller MA; Sagnella GA; MacGregor GA
    Hypertension; 1991 Dec; 18(6):798-804. PubMed ID: 1835959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Interaction on metabolic clearance between A-type and B-type natriuretic peptides in patients with heart failure.
    Yoshimura M; Mizuno Y; Harada E; Nakayama M; Shimasaki Y; Ito T; Nakamura S; Soejima H; Miyamoto S; Takazoe K; Ogawa H; Kugiyama K; Saito Y; Nakao K; Yasue H
    Metabolism; 2000 Sep; 49(9):1228-33. PubMed ID: 11016910
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Acute inhibition of endopeptidase 24.11 in essential hypertension: SCH 34826 enhances atrial natriuretic peptide and natriuresis without lowering blood pressure.
    Richards AM; Crozier IG; Espiner EA; Ikram H; Yandle TG; Kosoglou T; Rallings M; Frampton C
    J Cardiovasc Pharmacol; 1992; 20(5):735-41. PubMed ID: 1280735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Atrial natriuretic factor-potentiating and antihypertensive activity of SCH 34826. An orally active neutral metalloendopeptidase inhibitor.
    Sybertz EJ; Chiu PJ; Vemulapalli S; Watkins R; Haslanger MF
    Hypertension; 1990 Feb; 15(2):152-61. PubMed ID: 2154404
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of chronic neutral endopeptidase inhibition on cardiac hypertrophy after experimental myocardial infarction.
    Yoshida K; Yasujima M; Casley DJ; Johnston CI
    Jpn Circ J; 1998 Sep; 62(9):680-6. PubMed ID: 9766707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of SCH 34826, a neutral endopeptidase inhibitor, on hypoxic pulmonary vascular remodelling.
    Stewart AG; Sheedy W; Thompson JS; Morice AH
    Pulm Pharmacol; 1992 Jun; 5(2):111-4. PubMed ID: 1535251
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clearance receptors and endopeptidase: equal role in natriuretic peptide metabolism in heart failure.
    Rademaker MT; Charles CJ; Kosoglou T; Protter AA; Espiner EA; Nicholls MG; Richards AM
    Am J Physiol; 1997 Nov; 273(5):H2372-9. PubMed ID: 9374774
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Practical implications of current natriuretic peptide research.
    Sagnella GA
    J Renin Angiotensin Aldosterone Syst; 2000 Dec; 1(4):304-15. PubMed ID: 11967816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relationship between plasma levels of immunoreactive atrial natriuretic hormone and hemodynamic function in man.
    Bates ER; Shenker Y; Grekin RJ
    Circulation; 1986 Jun; 73(6):1155-61. PubMed ID: 2938846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition.
    Cruden NL; Fox KA; Ludlam CA; Johnston NR; Newby DE
    Hypertension; 2004 Dec; 44(6):913-8. PubMed ID: 15492133
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Secretion of atrial natriuretic peptide from the heart in man.
    Singer DR; Dean JW; Buckley MG; Sagnella GA; MacGregor GA
    Br Heart J; 1987 Jul; 58(1):24-8. PubMed ID: 2956978
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of the dual metallopeptidase inhibitor, MDL 100,240, on regional haemodynamic responses to vasoactive peptides in conscious rats.
    Gardiner SM; Kemp PA; Brunner-Ferber F; Bennett T
    Br J Pharmacol; 1997 Dec; 122(8):1687-93. PubMed ID: 9422815
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of SCH 34826, an orally active inhibitor of atrial natriuretic peptide degradation, in healthy volunteers.
    Burnier M; Ganslmayer M; Perret F; Porchet M; Kosoglou T; Gould A; Nussberger J; Waeber B; Brunner HR
    Clin Pharmacol Ther; 1991 Aug; 50(2):181-91. PubMed ID: 1831083
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Plasma brain natriuretic peptide and atrial natriuretic peptide concentrations correlate with left ventricular end-diastolic pressure.
    Haug C; Metzele A; Kochs M; Hombach V; Grünert A
    Clin Cardiol; 1993 Jul; 16(7):553-7. PubMed ID: 8348764
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of the neutral endopeptidase inhibitor, SCH 42495, on the cardiovascular remodelling secondary to chronic hypoxia in rats.
    Thompson JS; Sheedy W; Morice AH
    Clin Sci (Lond); 1994 Jul; 87(1):109-14. PubMed ID: 8062513
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Candoxatril, an orally active neutral endopeptidase inhibitor, raises plasma atrial natriuretic factor and is natriuretic in essential hypertension.
    O'Connell JE; Jardine AG; Davidson G; Connell JM
    J Hypertens; 1992 Mar; 10(3):271-7. PubMed ID: 1315825
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A 94-kDa protein, identified as neutral endopeptidase-24.11, can inactivate atrial natriuretic peptide in the vascular endothelium.
    Soleilhac JM; Lucas E; Beaumont A; Turcaud S; Michel JB; Ficheux D; Fournié-Zaluski MC; Roques BP
    Mol Pharmacol; 1992 Apr; 41(4):609-14. PubMed ID: 1533267
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Specific inhibitors of endopeptidase 24.11 inhibit the metabolism of atrial natriuretic peptides in vitro and in vivo.
    Olins GM; Krieter PA; Trapani AJ; Spear KL; Bovy PR
    Mol Cell Endocrinol; 1989 Feb; 61(2):201-8. PubMed ID: 2521834
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anemia is an independent predictor for elevated plasma levels of natriuretic peptides in patients undergoing cardiac catheterization for coronary artery disease.
    Fukuta H; Ohte N; Mukai S; Saeki T; Kobayashi K; Kimura G
    Circ J; 2008 Feb; 72(2):212-7. PubMed ID: 18219156
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.